You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Details for Patent: 10,814,002


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,814,002
Scope and claims summary:
Title:Patch and method for producing the same
Abstract: A method for producing a patch including a support layer, and an adhesive agent layer formed on the support layer and including sodium diacetate, a pressure-sensitive adhesive base agent, and asenapine and/or a pharmaceutically acceptable salt thereof. The sodium diacetate is generated from sodium acetate in the presence of the asenapine and/or salt thereof, a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is in range of 3.0 to 20 mg, and when a content of the asenapine and/or salt thereof in terms of free asenapine in the adhesive agent layer is 6.4 mg and the patch is in contact with skin for 24 hours, C.sub.max of free asenapine is in range of 0.5 to 6.0 ng/mL and t.sub.max of free asenapine is in range of 8 to 28 hr.
Inventor(s): Suzuki; Masayuki (Tsukuba, JP), Okutsu; Hiroaki (Tsukuba, JP), Yasukochi; Takashi (Tsukuba, JP), Takada; Yasunori (Tsukuba, JP)
Assignee: HISAMITSU PHARMACEUTICAL CO., INC. (Tosu-shi, JP)
Application Number:16/209,084
Patent Claim Types:
see list of patent claims
Use; Compound;

Drugs Protected by US Patent 10,814,002

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-001 Oct 11, 2019 RX Yes Yes 10,814,002 ⤷  Subscribe Y METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH ⤷  Subscribe
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-002 Oct 11, 2019 RX Yes No 10,814,002 ⤷  Subscribe Y METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH ⤷  Subscribe
Hisamitsu SECUADO asenapine SYSTEM;TRANSDERMAL 212268-003 Oct 11, 2019 RX Yes No 10,814,002 ⤷  Subscribe Y METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,814,002

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2012-165793Jul 26, 2012
Japan2013-078583Apr 4, 2013

International Family Members for US Patent 10,814,002

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 104487071 ⤷  Subscribe
China 104487072 ⤷  Subscribe
China 104507472 ⤷  Subscribe
European Patent Office 2878298 ⤷  Subscribe
European Patent Office 2878299 ⤷  Subscribe
European Patent Office 2878300 ⤷  Subscribe
Spain 2632946 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.